111 related articles for article (PubMed ID: 7855389)
1. [Interferon-alpha in the treatment of myeloproliferative syndromes].
Ballarino P; Castello G; Lerza R
Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389
[TBL] [Abstract][Full Text] [Related]
2. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
Skotnicki AB; Wolska-Smoleń T
Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
[TBL] [Abstract][Full Text] [Related]
3. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
Elliott MA; Tefferi A
Semin Thromb Hemost; 1997; 23(5):463-72. PubMed ID: 9387205
[TBL] [Abstract][Full Text] [Related]
6. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
Hasselbalch HC
Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
[TBL] [Abstract][Full Text] [Related]
7. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
10. Transplant decision-making strategies in the myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Kiladjian JJ; Chomienne C; Fenaux P
Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
[TBL] [Abstract][Full Text] [Related]
12. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
[TBL] [Abstract][Full Text] [Related]
13. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Kantarjian HM; Talpaz M
Semin Oncol; 1994 Dec; 21(6 Suppl 14):8-13. PubMed ID: 7992099
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera].
Sumi M; Tauchi T; Takaku T; Ohyashiki JH; Ohyashiki K
Rinsho Ketsueki; 2005 Nov; 46(11):1208-12. PubMed ID: 16440805
[TBL] [Abstract][Full Text] [Related]
16. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update.
Sacchi S
Leuk Lymphoma; 1995 Sep; 19(1-2):13-20. PubMed ID: 8574158
[TBL] [Abstract][Full Text] [Related]
17. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
18. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
19. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha in the treatment of chronic myelogenous leukemia.
Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
